Weight-loss drugs are an issue for McDonald's, but here's the bigger problem

Redburn Atlantic downgraded McDonald's to "sell" citing concerns over GLP-1 weight-loss drugs, tempered growth expectations, and pricing fatigue, leading to a 1.3% intraday stock decline and a potential seven-day losing streak; the firm also highlighted McDonald's challenged core value perception and traffic erosion among its core customer base due to years of outsized pricing, with comparable sales already decreasing 1% globally and 3.6% in the U.S.; the report also initiated coverage of Domino's with a sell rating, Chipotle with a neutral rating, and upgraded Yum! Brands to "buy", noting traffic softness already pressuring results for Domino's and McDonald's.

Analysis

Redburn Atlantic's downgrade of McDonald's Corp. (MCD) stock to "sell" from "buy" triggered a 1.3% intraday stock decline on Tuesday, potentially marking its seventh consecutive day of losses, the longest such streak since August 2013. The downgrade is attributed to mounting concerns over the impact of GLP-1 weight-loss drugs, moderated growth expectations, and particularly significant "pricing fatigue." While the immediate sales impact from GLP-1 drugs on most fast-food brands is currently described as minor by Redburn Atlantic analyst Chris Luyckx, he highlights a cumulative risk, warning that a 1% drag today could escalate to 10% or more over time, disproportionately affecting brands catering to lower-income consumers or group dining occasions due to broader behavioral shifts in group and household routines.

For McDonald's specifically, "pricing fatigue" and a "core value perception [that] appears to be increasingly challenged" are paramount concerns, as noted by Luyckx, stemming from years of outsized pricing. This has resulted in soft traffic, notably in the U.S., with core customers reducing visit frequency. These observations are underscored by McDonald's recent first-quarter results, where comparable sales fell 1% globally and 3.6% in the United States. Company leadership acknowledged these pressures; CEO Chris Kempczinski remarked on customers becoming more judicious and cutting back visits, especially for breakfast, while CFO Ian Borden pointed to inflationary and interest rate pressures on lower-income U.S. consumers, which are now also affecting middle-income demographics.

These challenges extend across the fast-food sector, with most brands experiencing consistently negative guest counts despite what the analyst terms robust pricing power. For instance, Chipotle Mexican Grill Inc. (CMG) saw its comparable sales decline for the first time since 2020 in its recent first quarter, and Domino’s Pizza Inc. (DPZ) also reported a drop in U.S. comparable sales. Reflecting this environment, Redburn Atlantic initiated Domino's with a "sell" rating and Chipotle with "neutral," while upgrading Yum! Brands Inc. (YUM) to "buy." The broker noted that McDonald’s and Domino’s face the "greatest near-term risk" due to existing traffic softness, whereas Chipotle and Yum! Brands seem "better positioned," supported by category momentum. According to the article, McDonald’s shares are up 3.8% in 2025, Domino’s stock is up 8.8%, Chipotle shares are down 15.9%, and Yum! Brands’ stock is up 6.7%, compared to the S&P 500 index's 2.5% gain this year.

Key Decisions for Investors

• Given Redburn Atlantic's "sell" rating on McDonald's, driven by significant pricing fatigue, declining U.S. comparable sales of 3.6% in Q1, and eroding core customer traffic, investors should re-evaluate exposure to MCD, closely monitoring for any strategic shifts to restore value perception or further signs of market share loss.
• Investors might consider Redburn Atlantic's view that Yum! Brands (upgraded to "buy") is better positioned due to category momentum, potentially offering a more favorable risk-reward profile compared to McDonald's and Domino's (initiated at "sell"), both of which are already showing pressure from traffic softness.
• The pervasive issue of weak traffic across the fast-food sector, coupled with the emerging long-term threat from GLP-1 drugs and persistent inflationary pressures on consumers, warrants a cautious stance; focus should be on brands demonstrating resilient traffic, strong value propositions, or unique category advantages.